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Abstract
Background: At present, the relatively sudden appearance and explosive spread of HIV throughout Africa and around 
the world beginning in the 1950s has never been adequately explained. Theorizing that this phenomenon may be 
somehow related to the eradication of smallpox followed by the cessation of vaccinia immunization, we undertook a 
comparison of HIV-1 susceptibility in the peripheral blood mononuclear cells from subjects immunized with the 
vaccinia virus to those from vaccinia naive donors.
Results: Vaccinia immunization in the preceding 3-6 months resulted in an up to 5-fold reduction in CCR5-tropic but 
not in CXCR4-tropic HIV-1 replication in the cells from vaccinated subjects. The addition of autologous serum to the cell 
cultures resulted in enhanced R5 HIV-1 replication in the cells from unvaccinated, but not vaccinated subjects. There 
were no significant differences in the concentrations of MIP-1α, MIP-1β and RANTES between the cell cultures derived 
from vaccinated and unvaccinated subjects when measured in culture medium on days 2 and 5 following R5 HIV-1 
challenge.
Discussion: Since primary HIV-1 infections are caused almost exclusively by the CCR5-tropic HIV-1 strains, our results 
suggest that prior immunization with vaccinia virus might provide an individual with some degree of protection to 
subsequent HIV infection and/or progression. The duration of such protection remains to be determined. A differential 
elaboration of MIP-1α, MIP-1β and RANTES between vaccinated and unvaccinated subjects, following infection, does 
not appear to be a mechanism in the noted protection.
Background
A number of studies [1-4] have examined the origins of
the human immunodeficiency virus (HIV) epidemic.
Using epidemiological analyses and computer modelling,
they have suggested that HIV-1 arose sometime around
1931 (1915-1941) from the simian immunodeficiency
virus (SIVcpz) found in chimpanzees (Pan troglodytes
troglodytes) of sub-Saharan, western central Africa, while
HIV-2 is estimated to have independently arisen in west-
ern Africa about a decade later, 1940 ± 16 years, from the
SIV (SIVsm) of sooty mangabeys (Cercocebus atys).
Beginning in the mid to late 1950s, both types of HIV
entered a phase of exponential spread, first within Africa
and then around the world. Wars, the reuse of unsteril-
ized needles and other medical equipment in Africa dur-
ing the 1950s and 1960s, and the contamination of early
batches of polio vaccine in the 1950s have all been sug-
gested as possible explanations for the emergence and
spread of HIV . However, all of these theories have been
either disproved or do not sufficiently explain the behav-
iour of the HIV pandemic [5-7]. The reasons behind
HIV's sudden emergence and the mechanisms underlying
its unique and highly successful adaptation to humans
have yet to be elucidated. Even with the development of
effective antiretroviral drugs, HIV continues to affect
tens of millions of victims throughout the world and to
ravage most of Sub-Saharan Africa as well as many large
areas in Asia and Eastern Europe. The search for an effec-
tive HIV vaccine has thus far been intensive, expensive
and fruitless.
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The eradication of smallpox and the cessation of world-
wide vaccinia-based vaccination programs--events that
occurred in the mid-20th century--have not been previ-
ously explored as a potential factor in the emergence and
rapid spread of HIV. The suggestion that the progression
of HIV-1 infection may be mitigated by an unrelated viral
co-infection is not new. Co-infection with human herpes-
virus 6 or 7 (HHV-6 or HHV-7) [8,9], GB virus C (GBV-
C) [10], dengue fever virus [11], or the paramyxovirus
responsible for measles [12,13] has been shown to medi-
ate an inhibition of HIV-1 in vivo or in vitro. This inhibi-
tion appears to be mediated through the upregulation of
CC chemokine receptor 5 (CCR5)-specific ligands and
other cytokines, or by the downregulation of CD4 in the
case of HHV-7. When the co-infecting virus can no lon-
ger be detected in the host, the protective effect seems to
disappear in most cases.
One possible mechanism for the proposed relationship
between HIV and pox viruses comes from the well known
exploitation of CCR5 by HIV as a co-receptor to initiate
infection in CD4+ lymphocytes and mononuclear cells
[14,15]. Individuals homozygous for the CCR5Δ32 muta-
tion--a null mutation of CCR5--are highly resistant to
infection with HIV-1 [16,17]. Growing evidence suggests
that many pox viruses, including vaccinia and variola
require the presence of CCR5 as a permissive factor to
generate a successful infection of some cells and preferen-
tially infect CCR5-positive T cells [18-21]. As a conse-
quence, it is possible that infection with some poxviruses
may alter the expression of CCR5 on cell surfaces and/or
t h e  p r o d u c t i o n  o f  C C R 5 - s p e c i f i c  l i g a n d s .  S u c h  e v e n t s
might interfere with a concurrent or subsequent infection
by HIV-1.
Based on these data, we hypothesized that vaccinia
immunization might confer some protection against ini-
tial HIV infection and possibly even disease progression.
To test this hypothesis, we compared, in vitro, the suscep-
tibility of peripheral blood mononuclear cells (PBMCs)
from 10 vaccinia naïve subjects to those of 10 subjects
immunized against smallpox no less than 3 and no more
than 6 months prior to this study.
Methods
Subject selection
This study was approved by the institutional review
boards of George Mason University, George Washington
University and Potomac Hospital, and was conducted in
accordance with the Helsinki Declaration. All subjects
received both verbal and written informed consent and
were told that results would be used in a study for poten-
tial publication. Twenty healthy volunteers were chosen
from a group of naval personnel with a range in age of 19
to 41 years. Subjects included male and female, and white
and non-white individuals. All subjects had a similar mix
of previous immunizations with the exception that 10
subjects had been immunized with Dryvax (Wyeth)
within the previous 3 to 6 months, and 10 subjects were
vaccinia naive. Successful vaccination was confirmed by
repeated visual inspections demonstrating the expected
progression of the vaccination site. All subjects had a
negative HIV test within the previous year. Two tubes of
heparinized blood and one serum separator tube were
collected. All blood samples from all subjects were drawn
within 6 hours of each other and were immediately pro-
cessed to separate the PBMCs using standard methods of
Ficoll-Hypaque centrifugation [22,23]. After the cell cul-
tures were started one vaccinated subject was dropped
from the study because we learned that this individual
had been having recurrent outbreaks of localized cutane-
ous vaccinia for several months since the vaccination.
Since this might indicate an underlying occult health
problem or immune deficiency it made the subject
unsuitable for our study.
Cell culture preparation
PBMCs were centrifuged at 1200 rpm for 11 minutes and
resuspended in RPMI tissue culture medium + 10% fetal
calf serum + 10 μg/ml gentamicin at a concentration of 1-
3 × 106 cells/ml with a final concentration of 2 × 106 cells/
culture. Cell cultures were incubated at 37°C in a CO2
incubator for 2 days then either an R5 strain (HIV-1ADA)
or an X4 strain (HIV-1NL4-3) was mixed with an equal vol-
ume of either culture medium or serum from each indi-
vidual subject and then incubated on ice for 7 hours after
which 175 μl of each mixture was inoculated into the
appropriate autologous cell cultures. No specific culture
activating substances were added. After an overnight
i n c u b a t i o n ,  t h e  c e l l  c u l t u r e s  w e r e  w a s h e d  w i t h  t h e
described culture medium to remove non-attached viri-
ons. 150 μl of supernatant were aspirated for RT and/or
chemokine analysis from each culture tube on days 2, 5, 8,
10, and 13. Beginning on day 8, half of the medium was
changed after each supernatant collection.
Reverse Transcriptase (RT) analysis
The measurements of viral replication were performed by
standard RT assays using tritium-labelled thymidine as
described elsewhere [22].
Chemokine analysis
Levels of MIP-1α, MIP-1β and RANTES in culture super-
natants were determined by specific ELISA (R&D Sys-
tems, Minneapolis, MN) according to the manufacturer's
protocol.
Statistical Analysis
Student's two-tailed, paired t test was used to determine
statistical significance.Weinstein et al. BMC Immunology 2010, 11:23
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Results and Discussion
All results are based on RT analysis using tritiated thymi-
dine, and are given in counts per minute (cpm/μL). Cul-
tures with no HIV added served as the negative control
for the determination of background radioactivity. All of
these control cultures had mean RT values of less than
100 cpm/μL on all days with no difference between vacci-
nated and unvaccinated subjects.
Figure 1 shows the results from cultures infected with
R5 HIV-1ADA. Without autologous serum pre-treatment
(Figure 1a), a statistically significant mean reduction of
HIV-1ADA replication was observed in cultures from vac-
cinated subjects when compared to unvaccinated sub-
jects on days 10 (nearly 3 fold, p = 0.035) and 13 (4 fold, p
= 0.017). Similar results were observed in cultures started
with autologous serum pretreatment (Figure 1b), with a
greater than 3 fold decrease by day 10 (p = 0.013) and a 5
fold decrease by day 13 (p = 0.008). R5 HIV-1 replication
i n  c e l l s  f r o m  u n v a c c i n a t e d  s u b j e c t s  w i t h  a u t o l o g o u s
serum pretreatment was greater on nearly all days com-
pared to viral replication in cells from the same subjects
without autologous serum. This is likely due to the acti-
vating effects of the serum on the cultured PBMCs. No
such activation of viral replication occurred in cultures
from vaccinated subjects with autologous serum pre-
treatment, which remained nearly identical to that of cul-
tures without the autologous serum, suggesting that vac-
cination prevented the enhancement of viral replication
Figure 1 Comparison of R5 HIV-1ADA replication in PBMC cultures from vaccinia naïve (N-10) and vaccinia vaccinated (N = 9) subjects. Figure 
1a shows cultures without and figure 1b shows cultures with pretreatment with autologous serum. A reduction in HIV replication can be seen on days 
10 and 13. *p < 0.05 **p < 0.01.
Figure 2 Comparison of X4 HIV-1NL4-3 in PBMC cultures from vaccinia naïve (N = 10) and vaccinia vaccinated (N = 9) subjects. Figure 2a shows 
cultures without and figure 2b shows cultures with pretreatment with autologous serum. No statistically significant difference between the vaccinat-
ed and unvaccinated subjects is found, however there is a trend toward reduced viral replication in the vaccinated subjects.Weinstein et al. BMC Immunology 2010, 11:23
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by the serum. This enhancement of HIV-1 replication in
cultures infected in the presence of autologous serum in
the unvaccinated subjects is responsible for the greater
divergence seen between vaccinated and unvaccinated
subjects in Figure 1b compared to Figure 1a.
In cultures infected with X4 HIV-1NL4-3 (Figure 2) no
statistically significant difference in viral replication
between cells from vaccinated and unvaccinated subjects
is observed although there is a trend toward reduction in
HIV replication in vaccinated subjects. Pretreatment with
autologous serum (Figure 2b) does not appear to make
any difference in the replication of HIV-1NL4-3 when com-
pared to non-pretreated cultures (Figure 2a). These find-
ings suggest little if any effect by vaccinia immunization
on replication of CXCR4-tropic HIV-1.
Within the narrow 3-6 month time frame of this study,
there did not appear to be any relationship between the
time since vaccination and the level of viral replication
(data not shown). Cells from subjects vaccinated 6
months prior to the study showed similar reductions of
viral replication to those in cells from subjects vaccinated
3 months before the study. This prolonged effect of vacci-
nation is significantly different from that seen with other
viruses known to inhibit HIV replication (measles, den-
gue fever virus and GBV-C), where such inhibition can
onl y be  de m ons t ra t ed during  t he lif e  o f  t he  a ct ua l c o-
infection and disappears when the co-infecting virus is no
longer detectable [11,13,24]. Additionally, subsequent to
this study, two of our co-authors independently repeated
this study as part of a much larger investigation looking
primarily at long term chemokine production after multi-
ple immunizations [25]. In their study, they were able to
demonstrate reduced CCR5-tropic HIV-1 replication in
PBMC cultures from vaccinia immunized subjects vacci-
nated up to 14 months prior to their study. A statistically
significant reduction in replication did not occur in cul-
tures infected with a CXCR4-tropic HIV-1, although
there was a trend toward reduced replication. Their
results are nearly identical to those reported in this study,
suggesting that an as-yet-to-be-identified suppressive
Figure 3 Chemokine analysis in culture supernatants. Comparison of MIP-1α (a), MIP-1β (b) and RANTES (c) release between the PBMCs from vac-
cinated (N = 9) and unvaccinated (N = 10) subjects on days 2 and 5 post culture inoculation with HIV-1ADA. No significant difference between the vac-
cinated and unvaccinated subjects is apparent. Figure 3d shows chemokine levels from non-infected control cultures (N = 2 for each group) on culture 
day 5. There is a trend toward a higher baseline chemokine production in the vaccinated subjects, though it is not statistically significant.Weinstein et al. BMC Immunology 2010, 11:23
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effect on HIV replication is associated with vaccinia
immunization, and persists for an extended time follow-
ing vaccination, long after the vaccinia would be expected
to be cleared from the host.
In addition, Brichacek, et al. in the above referenced
study [25] demonstrated long term elevations of MIP-1α,
MIP-1β and IL-8 in the serum of vaccinia immunized
subjects compared to vaccinia naïve subjects. It is possi-
ble that these long term chemokine elevations may play
some role in the observed resistance of PBMCs from vac-
cinated subjects to HIV-1ADA replication. In the present
study we collected culture supernatant on days 2 and 5
following in vitro infection with HIV-1ADA for analysis of
MIP-1α, MIP-1β and RANTES. Despite an observed
trend towards higher levels of MIP-1α and MIP-1β in the
cultures of vaccinated subjects, no statistically significant
differences in the concentrations of those chemokines
were found between the PBMC culture supernatants of
vaccinated and unvaccinated subjects under our experi-
mental conditions (Figure 3a, b, c). While it is possible
that a long term elevation in baseline chemokine produc-
tion may confer some protection against HIV infection
and/or replication in vivo, an alteration in the ability of
the PBMCs from vaccinated subjects to secrete an excess
o f  t h e s e  c h e m o k i n e s  a s  a  r a p i d  r e s p o n s e  t o  a n  H I V - 1
challenge does not appear to play a role under these cul-
ture conditions. Interestingly, the levels of these chemok-
ines measured in the culture supernatant were generally
much lower in the uninfected control cultures (Figure
3d), with the exception of RANTES which demonstrated
levels equivalent to the HIV-1ADA infected cultures on
culture day 5, but only for the vaccinated subjects.
Though not statistically significant, there was also a trend
toward higher baseline levels of all 3 chemokines in the
vaccinated subjects, however the lack of statistical power
may be related to the fact that only 2 vaccinated and 2
unvaccinated subjects underwent chemokine analysis for
this control. The lack of statistical power prevents draw-
ing any conclusions concerning this finding.
Conclusions
Our findings support a heretofore unsuspected, yet sig-
nificant beneficial interaction between HIV-1 and the
pox virus vaccinia (and probably variola as well). Since
the difference was only seen with CCR5-tropic HIV-1
and not with CXCR4-tropic HIV-1, the apparent resis-
tance to HIV-1 in the vaccinated subjects is likely medi-
ated, at least in part, by alterations in CCR5 or its ligands.
However, our data suggest that this resistance is not
mediated by a sudden post-infection surplus release of
the chemokines MIP-1α, MIP-1β or RANTES in vaccinia
immunized subjects when compared to unvaccinated
subjects.
Most importantly, since primary HIV-1 infections are
caused almost exclusively by CCR5-tropic HIV-1 strains
[26] these results suggest that prior immunization with
vaccinia virus might play a role in providing an individual
with some degree of protection to subsequent HIV infec-
tion and/or disease progression. These results also pro-
vide some support to the hypothesis of a possible
relationship between smallpox eradication and the still
unexplained, sudden emergence of HIV-1. Further stud-
ies along these lines, involving larger groups of subjects
are needed to substantiate our results and to fully eluci-
date the mechanism at work.
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